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19 Background:   Effective   recruitment   to   randomised   controlled   trials   is   critically 
20 important for a robust, trustworthy evidence base in palliative care. Many trials fail to 
22 achieve   recruitment   targets,   but   the   reasons   for   this   are   poorly  understood. 
23 Understanding   barriers   and   facilitators   is   a   critical   step   in   designing  optimal 
24 recruitment strategies. 
25 
26 Aim: To identify, explore and synthesise knowledge about recruitment barriers and 
27 facilitators   in  palliative  care  trials  using  the  ‘6  Ps’  of   the  ‘Social   Marketing  Mix 
29 Framework’. 
30 
31 Design: A systematic review with narrative synthesis. 
32 
33 Data sources: Medline, Cinahl, PscyINFO and Embase databases (from Jan 1990 to 
34 early October  2016)  were searched.  Papers included: interventional and qualitative 
35 studies addressing recruitment,  palliative care randomised controlled trial papers  or 
36 reports containing narrative observations about the barriers, facilitators or strategies 
38 to increase recruitment. 
39 
40 Results: 48 papers met the inclusion criteria. Uninterested participants (Product), 
41 burden of illness (Price) and ‘identifying eligible participants’ were barriers. Careful 
42 messaging and the use of scripts/role play (Promotion) were recommended. The 
43 need for intensive resources and gatekeeping by professionals were barriers while 
45 having research staff on site and lead clinician support (Working with Partners) was 
46 advocated. Most evidence is based on researchers own reports of experiences of 
47 recruiting to trials rather than independent evaluation. 
48 
49 Conclusions:  The  ‘Social  Marketing  Mix  Framework’  can  help  guide  researchers 
50 when  planning  and implementing their  recruitment strategy  but suggested  strategies 
52 need  to  be  tested  within  embedded  clinical  trials.  The  findings  of  this  review are 












Uninterested participants (Product), burden of illness (Price), ‘identifying eligible 
participants’, the need for intensive resources and gatekeeping by professionals 
(Working with Partners) are barriers to recruitment. 
Careful messaging, the use of scripts/role play (Promotion), having research staff 
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11 Key Messages 
12 
13 What is already known about the topic? 
14 
15  More randomised controlled trials (RCTs) are required in palliative care to 
16 provide the evidence to underpin our clinical practice and care. 
18  Palliative care RCTs struggle to achieve their recruitment targets. 
19  The evidence related to the barriers and facilitators to recruitment in palliative 
20 care has not yet been synthesised. 
21 










Implications for practice, theory or policy? 
33 
 Current evidence about the barriers and facilitators to recruitment to RCTs in 
35 palliative care is mostly anecdotal. 
36  The ‘Social Marketing Mix Framework’ can help guide researchers when 
37 planning and implementing their recruitment strategy. 
38  More methodological research is needed to help improve recruitment rates to 
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6 Recruiting the required number of participants to palliative care research studies is 
7 challenging. People can often be ‘hard to reach’ as they have a diverse range of 
8 conditions, are cared for in a wide variety of clinical settings and have unpredictable 
9 and complex needs. Recruitment to randomised controlled trials (RCTs) is especially 
10 difficult as there are inherent challenges associated with this type of research such 
11 as patient1, 2 or clinician3 concerns about assignment to a non-preferred treatment 
12 arm or to a placebo arm. While recruitment challenges apply to all RCTs, 4, 5 these 
13 issues are often heightened in palliative care research as the study population is 
14 particularly vulnerable and ‘there is often no second opportunity to improve care’ (p 
15 70).6 The difficulty of recruiting participants to palliative care RCTs is reflected in the 




20 We require adequately powered RCTs to evaluate the safety and effectiveness of 
21 health care interventions.This is not only essential to deliver high quality end of life 
22 care but is increasingly important as palliative care attempts to justify its role within a 
23 complex and resource limited health care system. As an example, an important 
24 recent trial finding is that antipsychotic drugs are not beneficial in reducing symptoms 
25 of delirium. These findings could be put into practice more rapidly had it not taken 
26 over 5 years to reach the target sample size.
10 
27 
28 Why so many palliative care RCTs struggle or fail to achieve their recruitment targets 
29 is an important area of clinical practice that is poorly understood. The use of a 
30 memory aid, contact before arrival, cluster consent and ‘opt out’ consent improved 
31 recruitment of people with cancer or organ failure into trials.11 Strategies that reduce 
32 the demand on health care professionals such as a clinical recruiter or automated 
33 alert system were seen as the most promising strategies in a review focusing on 
34 research studies in general but the studies that were assessed were at high risk of 
35 bias.12 Individuals or organisations prevent eligible patients from entering a palliative 
37 care research study because of personal feelings, perceptions and intuitions rather 
38 than a formal assessment that involves the patient.
13 
39 
40 This review is unique as it uses a theoretical framework, the ‘Social Marketing Mix 
41 Framework’, to explore recruitment barriers, facilitators and strategies in palliative 
42 care RCTs.
14 Marketing focuses its efforts on meeting the needs of customers by 
43 understanding the factors that can influence their decisions to buy a product or sign 
44 up to a particular scheme.
15 Social marketing has been used in public health for 
45 many years and applies marketing principles to programmes that aim to influence 
46 the behaviour of a particular audience to improve their welfare or that of society as a 
47 whole.
14 The ‘Social Marketing Mix Framework’ has been seen as a potentially useful 
48 theoretical framework to help organise and plan recruitment activities as well as help 
49 to identify factors that can be adjusted to maximise enrollment.
14 It has been applied 
50 to trials recruiting the caregivers of patients with Alzheimer’s disease
14, 16 and 
51 elements of the framework have been used in a successfully recruiting palliative care 
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1 Recruitment SR 
2 
3 
4 The aim of this review is to identify, explore and synthesise what is known about the 
5 recruitment barriers and facilitators in palliative care RCTs using the ‘6 Ps’ of the 
6 ‘Social Marketing Mix Framework’ in order to develop recommendations that can be 
7 used to increase recruitment in clinical practice. The ‘6 Ps’ used are: ‘Identifying 
8 participants’ which is defining your target audience, the ‘Product’ which is the 
9 intervention, the ‘Price’ which is the cost of taking part in the study for participants, 
10 the ‘Place’ is where recruitment activity takes place, ‘Promoting the study’ is how you 
12 reach your target population and ‘Working with partners’ relates to organisations or 






19 Review Question 
20 
21 What can the ‘6 Ps’ of the ‘Social Marketing Mix Framework’ tell us about the 
22 recruitment barriers and facilitators in palliative care RCTs? 
23 
24 Review Design 
25 
26 A narrative approach to synthesis was chosen as this facilitates the incorporation of 
27 research and non-research data, to provide new and valuable insights into complex 
28 trial recruitment processes.18 This review has been guided by a narrative synthesis 
29 framework made up of four elements18 as well as the ‘6 Ps’ that make up the ‘Social 
31 Marketing Mix Framework’. Below is a brief overview of how the four elements of the 
32 framework have been applied (see table 1) and further details are discussed within 
33 the relevant sections below. 
35 


















Element 1: The role of 
theory in evidence 
synthesis 
 
The ‘Social Marketing Mix Framework’ was the theory 
chosen.14 Theory in a review informs the data extraction 
process, contributes to the interpretation of findings and is 
valuable in assessing how widely applicable the findings 
may be in practice (p12).18 
Element 2: Developing 
a preliminary synthesis 
Descriptive data about each included study was organised 
into a table. Relevant sections of included papers were 
coded line by line using predetermined and open codes. 
Codes were then organised into categories and refined to 
develop broader themes. 
Element 3: Exploring 
relationships within and 
between studies 
Tabulation allowed themes to be conceptually mapped 
within the chosen theoretical framework. This allowed the 
most common themes across all of the studies to be 
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14 Search Strategy 
15 
16 Embase, Medline, psychINFO and CINAHL databases were searched from the 1st 
17 
January 1990 until the 8th October 2016 (see figure 1). The search included the 
19 terms palliat*, hospice* and ‘’terminal care’’ as they are seen as a robust and valid 
20 strategy to identify and retrieve palliative care literature. 19-21 The search terms used 
21 within Medline via EBSCO were palliat* or hospice* or terminal care or palliative 
22 care/ or palliative medicine/ or terminal care/ (not exploded) and randomi*ed 
24 controlled trial* or randomised controlled trial/ (publication and topic). The limits set 
25 were human, papers published between 01/01/1990 - 08/10/2016 and randomised 
26 controlled trials. The strategy was modified as necessary for the other databases 
27 searched. (see supplementary data table 1 for further details of the search terms 
29 used). The reference lists of the included studies were also hand searched to identify 
30 additional papers specifically focusing on recruitment to palliative care RCTs. 
31 
32 Study Eligibility 
33 
34 The inclusion and exclusion criteria are listed in table 2. Titles and abstracts were 
35 screened  by  a  reviewer  (LD)  to  identify  potentially  eligible  papers  and  another 
36 reviewer   independently  verified   10  %   (AO)  of   this   search.   One  reviewer  (LD) 























 or health care professional. 
Element 4: Assessing 
the robustness of the 
synthesis 
Under this approach, this involves an overall assessment 
of the strength of the evidence for drawing conclusions on 
the basis of the narrative synthesis and being thorough 
while critical of the methodological approach used to 




















Palliative Medicine Page 14 of 57 
 
1 Recruitment SR 
2 
3 














































 Adult cancer patients with incurable 
disease (defined by tumour staging)
 Non-professional carers of cancer 
patients with incurable disease





 Adults with a progressive, life 
threatening disease (defined by 
classifications of disease severity 
such as New York Heart Association 
Class, NB this would include patients 
classed in the literature as ‘frail 
elderly’ if they were receiving an 
intervention that was clearly a 
palliative care intervention.
 Non-professional carers of patients 
with a progressive, life threatening 
disease
 Parents of children with a 
progressive, life threatening disease
 
Study Design 
The types of papers listed below were 
included if they contained information about 
the barriers, facilitators or strategies to 
recruitment to palliative care RCTs: 
 Randomised Controlled Trials: 
Pilot/feasibility studies as well as full 
scale palliative care RCTs
 Intervention studies testing 
recruitment strategies
 Qualitative/observational studies 
that report barriers, facilitators or 
strategies to recruitment to palliative 
care RCTs
 Articles reporting narrative opinions 
and/or observations related to 
conducting a palliative care RCT
Study Population 
 
 Adult cancer patients with potentially 
curable disease 
 Care of chronic non-life threatening 
conditions without a curative 
treatment option 
 Those studies including patients with 
both curable and incurable disease if 
it is impossible to distinguish findings 
between groups 
 Primary endpoint of the study is 
survival or tumour/disease response 
(NB would be included if the study is 
testing an intervention that is clearly a 
palliative care intervention. 22 
 Neo adjuvant or adjuvant 
chemotherapy studies 
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5 Data Extraction 
6 
7 
8 NVivo 10 was used to support the data extraction and synthesis process. Descriptive 
9 data about each included study was extracted and organised into a table (see table 
10 4). Interview data from patients taking part in a palliative care RCT or professionals 
11 involved in recruitment to a RCT and it’s subsequent analysis reported in the 
13 included qualitative papers was extracted. Data in the form of narrative observations 
14 located in the discussion sections of RCT result papers or retrospective reports of 
15 researchers’ experiences of recruiting to a trial were also extracted. The amount of 
16 data extracted was variable across the included studies. Data extraction was carried 
18 out by one reviewer (LD) but 10% of the papers were independently verified (AO). 
19 
20 Data Synthesis 
21 
22 
23 Element 2: Developing a preliminary synthesis 
24 
25 Relevant sections of the included papers were initially coded line by line. A mixture 
26 of predetermined (priori) codes, the ‘6 Ps’ from the ‘Social Marketing Mix Framework’ 
27 (see table 3) 14 and open codes were used to ensure important aspects of the data 
29 were not missed during coding.23 Initial codes were then organised into the 
30 overarching categories  barriers,  facilitators and strategies in NVivo.  Strategies were 
31 viewed  as  interventions that  were implemented to support facilitators and overcome 
33 barriers. Within these categories codes were merged as appropriate and refined into 
34 broader themes. Coding into themes was carried out by one reviewer (LD) but 50 % 
35 (AO) of the papers coded were then independently checked by a second reviewer. 
36 
37 

















Social Marketing Mix Framework 






Defining the target audience (p4). 
Product 
 
Defining the product: 
 
The intervention is the product (its 
scientific, theoretical basis, does it meet 
the needs of the target audience?), the 
product must address a problem that is 
perceived as serious and amenable to 
the intervention (p4). 
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Element 3: Exploring relationships within and between studies 
31 
Tabulation allowed the overarching categories (barriers, facilitators and strategies) 
33 and the themes contained within them to be conceptually mapped with the ‘Social 
34 Marketing Mix Framework’ (see supplementary table 3). This allowed for the most 
35 common themes across all studies to be identified as well as how they apply to the 
36 patient, carer or health care professional. Potential strategies and facilitators that 
38 may help address identified barriers identified in the literature can also be visualised. 
39 
40 Quality Assessment 
41 
42 RCT papers were included to identify recruitment issues rather than assess 
43 robustness of findings therefore assessment of the methodological quality of these 
44 papers was not carried out. A hierarchy of evidence tool was adapted to assess the 
45 level of evidence the identified barriers, facilitators and strategies in the literature 
46 were based on (see supplementary data 2).24 No papers were excluded based on 
47 their evidence scoring. This approach was used as the methodology of included 
48 papers was mixed and the majority contained non-research evidence. This process 
49 allowed judgements to be made about the quality of evidence and the weight that 




The product’s competition: participant’s time and energy (p5). 
Price The cost to the potential participant of 
taking part in the study (e.g. financial, 
time, physical and emotional effort). 
Things need to consider: type of costs 
and how to minimise the costs (p5-6). 
Place (Improving accessibility) ‘The location where the participant will 
receive information about, or engage in, 
the intervention’ (p6). 
Promoting the study ‘Identify the acceptable avenues that 
reach the target population’ (p7). 
Working with partners ‘Partners are defined as organisations 
involved with a social change effort or 
serving as conduits to target audiences’ 
(p8). Things to consider: partner 
education, partner referrals and 
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1 Recruitment SR 
2 
3 
4 This review includes studies testing recruitment strategies (n=3), qualitative 
5 explorations of recruitment issues (n=3) and trial reports (n=14) reporting barriers 
6 and facilitators to recruitment. Most (n=28) were methodological papers exploring the 
8 design of exemplar trial/s. A contextual summary of the included papers with the 














































data) provides a visual overview of how the evidence is weighted within the ‘6 Ps’.14 
mapped within the ‘working with partners’ category and table 3 (see supplementary 























7 Reference Type of 





























13 1 Abernethy et 










used in a RCT. 
All of the article. 
To evaluate the 
safety and 



















laxative (2 arms with 
different doses) Control: 
placebo 
questionnaires 2 a 
and blood 
samples 










30 3 Bakitas et al28, 
31 linked to Bakitas 














reasons for non- 
participation in a 
RCT. 
All of the article. 
 
 
















































































































and other persons 
living with 
advanced cancer. 































2 Recruitment SR 
3 
4 
5 Reference Type of 





























11 4 Bakitas et al29, 
12 linked to Bakitas 












































care intervention model 
Control: usual care 
questionnaires 2 a 
 
semi structured 
interview with a 
subgroup of 
participants 






















































Control: usual care 
not stated 2 a 










A paper reporting 
the findings from 





















Phase II RCT 




advanced lung cancer or COPD 












patients in each 




recruited to the 
main study of 
which 70 took 
part in the RCT 
Intervention: hand 
held fan Control: 
a wristband to 
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5 Reference Type of 





























11 7 Buss and 


















report of the 
experiences of 
researchers who 
attempted to set 

















To examine the 
impact of CHESS 
on caregiver 
outcomes of 














































Intervention: anti emetic 





Intervention: a web- 
based information and 
support system 
(CHESS) Study 1 
CHESS and clinician 
rapport or CHESS 
Study 2 CHESS and 
clinician rapport or 
control access to 
computer/internet 






survey 2 a 
27 















A paper reporting 
the findings of a 
phase II RCT. 
Discussion 
section. 
To assess the 
feasibility of 
early consent 








the end of life. 
























N=from April to 
November 2001, 49 
consented 21 
randomised 
Intervention: Participants while well 
and their proxies provided written 
informed consent. If NB were 
encountered, people were 
randomized to 200 mcg octreotide 
or 400 mcg hyoscine hydrobromide 
subcutaneously. If subsequent 
treatment was needed, the other 









































2 Recruitment SR 
3 
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5 Reference Type of 





































report of the 
experiences of 
researchers 
trying to recruit 
to a RCT. 
Introduction. 
To assess the 















N=4 over 5 
months 
not stated not stated 2 a 
11Currow et 
al36, linked to Le 
19 Blanc et al17 










in a large RCT 
and discusses 
























The ‘Palliative Care 




and patient education 
questionnaires 2 a 















A paper reporting 






recruitment to a 
RCT. 
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5 Reference Type of 





























11 13 Farquhar et 
12 al39 linked to 












To test the 
feasibility of a 
single-blinded fast 
track pragmatic 

























immediately for eight 
weeks or after an eight 
week period on a 
waiting list during which 
time they received 
standard care. 
interviews and 2 a 
questionnaires 
19 14 Farquhar et 
20 al40 linked to 














in a RCT. All of 
the poster. 






Phase II pilot 
single-blind 
fast track RCT 















Control: not stated 
not stated 2 a 
15 Fischer et 
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21 17 Goldstein et 












































To evaluate the 
effect of a 
communication 
intervention on 















































each site (6 
sites) 












Both units used cluster 
randomisation or 
randomised consent for 
three months and then 
‘crossed over’ designs 











Control: no specific 
communication training, 
feedback or reminders 














32 18 Goodwin et 










recruitment to a 








































































2 Recruitment SR 
3 
4 
5 Reference Type of 





























11 19Gorman et 




























findings of a 
qualitative 
study. All of the 
paper. 
To compare the 
effect of home 









a palliative care 
RCT. Parent 
study: a RCT 
where patients 

































































Intervention: usual care 
supplemented by five 





statins  Control: 
continue statins 
questionnaires 2 a 
and daily logs 






























































Trial 1: 25 patients over 
36 months Trial 2: 14 
patients in 24 months, 
study terminated 
Intervention: IV dexamethasone 
Control: placebo, normal saline 
if obstruction still present at day 5, 
the patient was ‘crossed over’ to 
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11 22 Higginson et 





































N= 52, one 
year 
Intervention: an 
innovative palliative care 
service Control: the 
above after a > 3 month 
wait and until then 
received standard best 
practice 
interviews 2 a 
















To investigate a 
support and 
information 
programme for lay 











N=110 N=106 Intervention: nursing 

















impact of using 
different 
recruitment 


































pharmacists who had 
extra education in 
palliative care Control: 
pharmacists who had no 
additional education 
not stated 2a 
















lity and feasibility of a patient 
preference RCT of an ACP 
intervention. 
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3 
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5 Reference Type of 

































































To test the 




































































intervention plus usual 
care Control: usual care 
alone. Those in the 
control arm joined a 
wait-list and were 
offered the intervention 
three months after 
randomisation. 
Intervention: palliative 












questionnaires 2 a 




















































team meetings through 
video or phone 
conferencing Control: 
usual care 
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5 Reference Type of 












































25 31 Le Blanc et 
al17, linked to 
Currow et al36 



























report of the 
recruitment 
challenges 
faced during a 
RCT and how 
they were 
approached and 
overcome.  All 








To determine the 
effectiveness and 




























































































Intervention: the’ Patient 
Care Travelling Record’ 








conference with their GP 
versus control, (2) 
educational outreach 
visitation to GPs about 
pain management 
versus control, (3) 
structured educational 
visitation for patients 












































2 Recruitment SR 
3 
4 
5 Reference Type of 





























11 (New Zealand) reporting the 
12 findings and 
13 difficulties 
14 encountered 
15 during a 






Phase III RCT 
investigating the 
therapeutic value 















enrolled gastrografin Control: 
placebo 
33 McMillian 















the first year of 
a RCT with an 

























care plus supportive 
visits or standard care 
plus teaching of a 
method of coping with 
patient symptoms 
Control: standard care 
questionnaires 2 a 
29 34 McWhinney 



































N=110 per group N=146 Intervention: 
palliative care home 
support team Control: 
received intervention 






















usea and pain 
diary 
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12 linked to Miller 






recruiting to a 










6 months months, 98 
recruited 
designed to help 
patients prepare for `a 
good death’ Control: not 
stated 
17 
36 Miller et al61, 
18 
linked to Miller 













To evaluate the 





















Group Experience’ for 
reducing patient 
spiritual, emotional and 
death related distress. 
Control-standard care 
questionnaires 2 a 
37 Mitchell and 
Abernethy37 
linked to Le 
28 Blanc et al17 and 









38 A retrospective 
comparative 





































QCC N= 220 
 
PCT: N= 460 
QCC: N= 
randomised 159 (72%) 
of the target July 2001-May 
2003 
PCT: N= 
randomized 461 (100%) 
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3 
4 
5 Reference Type of 





























11 (UK) reporting the 
12 findings of a 
13 feasibility study 
14 to inform the 
15 design of a 
16 RCT. 
17 Qualitative study 













for treatment of 
cancer-associated 
thrombosis (CAT). 
To identify the 
practicalities of 














































treatment for CAT 
versus cessation of 






















To examine the 
effect of oxygen 
















N=50 N=51 over 
5 years 
Randomized to receive 
either air or oxygen via 
nasal prongs for 15 
minutes. Then, following 
a 30-minute interval 
without gas, repeat 
measurements were 
taken with crossover to 
the other gas for a 
further 15 minutes. 













38 40 Prentice et 














Intervention: a single 
application of 
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hydrochloride 3% cream 
to the painful pressure 
area. Control: placebo 




























39 A paper detailing 
a method of 
obtaining 
advance consent 
for a RCT and the 
interim 
recruitment 



















RCT of two 
anti- 
muscarinic 






























































From May to 
November 2002, 58 
patients consented Of 
these, 15 
developed death rattle 





August 2004 to 
November 2006 
Intervention: to receive either 
hyoscine or glycopyrronium at the 








Intervention: palliative care needs 
evaluation conducted by an 
interdisciplinary team, followed by 
ongoing nurse case management 
























































































































25 44 Shelby 68 


























A paper presenting suggestions 

















N/A 14 clinical 
studies were 
















N/A N/A To date, the Australian Palliative 
Care Clinical Studies Group has 
randomized more than 500 
participants 
across 12 
sites in 8 Phase III studies. 
Type of Aim original Method Sample Target Sample Type of Intervention Data Level 
article and study original and setting sample achieved /Control Collection of 
section  study of original over how over how   evidence 
recruitment   study long long    
was         
discussed         
A paper To assess the Initially a two- advanced N=40 N=33 Intervention: a palliative questionnaires 2 a 
reporting the feasibility arm feasibility dementia patient/ patients care patient assessment   
findings of a of implementing a cluster RCT and an carer dyads and carers which informed an ACP   
RCT. ACP intervention. then amended informal to each  discussion with the carer   
Discussion  to individual carer for study arm.  Control: usual care   
section.  level proxy      
  randomisation consent      
  
single hospital 
















































































32 47 Westcombe 







Type of Aim original Method Sample Target Sample Type of Intervention Data Level 
article and study original and setting sample achieved /Control Collection of 
section  study of original over how over how   evidence 
recruitment   study long long    
was         
discussed         
A letter outlining not stated 1 Placebo hospice/ not stated 1 N=not 1 Intervention: not stated 2a 
the challenges 
faced by a 
 RCT palliative 
care hospital 
 stated Mexilitine. for severe 
neuropathic pain 
  
researcher  2 RCT patients  2 screened Control: Placebo   
while trying to     almost 2 Intervention:   
recruit to three  3 RCT 1 hospices  2000 psychological   
RCTs. All of the   2 cancer  hospice intervention to increase   
letter.  multi centre centre and a  patients, 21 forgiveness Control: not   
   hospice  recruited stated.   
   3 hospital   3 Intervention: low dose   
   that  3 no oxycodone for   
   specializes in  patients in breathlessness in   
   cardiac care  a year advanced HF Control: 
not stated 
  
A paper To investigate the Cluster RCT incurable, 275 N= 99 Intervention: health-care questionnaires 2 a 
reporting the effect of a  life- patient– patients, providers took a spiritual   
findings of a structured multi centre threatening provider 245 HCPs, history on the basis of   
RCT. spiritual history  disease dyads. April to the ‘Ars moriendi’ model   
Discussion taking on the    October Control: usual care   
section. spiritual well-    2013    
 being of palliative  home care      
 patients in home        
 care.        
This paper To examine the RCT originally N=original N= 289 Intervention: questionnaires 2 a 
examines the effectiveness of  advanced target was over 4 aromatherapy massage   
challenges aromatherapy in multi centre cancer then 508, years, 75% Control: the first was a   
encountered in improving  included all reduced the longer than no-intervention control   
the design and psychological  stages of number expected. and the second   
execution of a distress and  cancer required  relaxation therapy.   
RCT. quality of life.   from 508 to  Relaxation therapy arm   
Main body   cancer 258.  removed during the trial.   











































































































































caregivers Control: not 
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2 
3 
4 1 Identifying participants: Defining the target audience 
5 
6 Barriers: Identifying participants who meet the study inclusion criteria/difficulty 
7 predicting prognosis 
8 
9 
The challenge of participant identification and complex inclusion criteria were raised 
10 
as issues. 30, 43, 46, 52, 57, 67, 70, 72 This can relate to the difficulty of predicting prognosis 
12 as part of the trial’s eligibility assessment, 36, 43, 45, 46, 56, 59 how palliative care is 
13 defined in a particular country70, too narrow and/or ambiguous inclusion criteria43, 57 
14 and lack of suitable caregiver72 or surrogate to gain proxy consent. 30, 67 
15 
16 
Facilitator: Broad study eligibility criteria 
17 
18 
Including broad study eligibility criteria in your protocol was seen as an aid to 
19 




23 Strategy: The use of a physician prognostication tool 
24 
25 The use of a physician prognostication tool to help define and identify those patients 
26 with an advanced life limiting illness who were likely to die within the next 12 months 
27 alongside face to face screening by a clinician was used as successful strategy in a 
28 RCT of an interdisciplinary palliative care needs evaluation.66 
30 
31 2 Developing the product: 
32 
33 Defining the product: 
34 
35 Barriers: Participants not interested/clinical equipose 
36 
37 A number of papers highlighted high refusal rates as an issue 27, 31, 33, 36, 55, 62, 71 with 
38 the lack of clinical equipoise being cited as a possible reason for this, with concerns 
39 about being randomised to their non-preferred arm having an influence on whether 
40 or not patients agreed to take part.62, 71 A lack of belief in the intervention,31, 33 the 
42 lack of an acceptable control,
31 the feeling the intervention was not needed at that 
43 particular time 
27, 33, 62 and competing priorities 55 were also cited as reasons for 
44 refusal. These concerns about the intervention, the control and randomisation also 
45 apply to health care professionals and may be one of the reasons for their 
47 gatekeeping. 
38, 52 32, 47, 71 44 
48 
49 Facilitator: Replicate clinical practice as much as possible 
50 
51 RCTs that replicated clinical practice in recruitment sites as closely as possible were 
52 seen to be more likely to be successful.68 If in recruitment sites clinical practice 
53 varied significantly from the processes outlined in the protocol, clinicians were likely 
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2 
3 
4 Facilitator: Offer a desirable and novel intervention 
5 
6 Offering a palliative care symptom control intervention to a group of patients who 
7 normally have limited access to such specialist input was suggested as a possible 
8 facilitator. 39 
10 
11 Strategies: Study design 
12 
13 A fast track design RCT with a short lead in time may have increased the response 
14 rate in a trial of a breathless intervention service as patients and families knew they 
15 were going to get the intervention either straight away or only after a short wait.
39 
16 There were reports of researchers simplifying their study design during the 
17 
18 recruitment phase of the trial. They reduced the number of study arms to reduce the 
19 number of participants required to ensure statistical power was achieved.
33, 71 
20 
21 There were strategies specifically suggested to help improve recruitment rates in 
22 drug trials. Giving patients the option to enter an extension study after taking part in 
23 a placebo controlled symptom control RCT was seen as important as enrolment was 
24 delayed for many patients until this was put into place.26 Clinician’s fears that 
26 patients will be left with uncontrolled symptoms if they are randomised to the control 
27 arm can be reduced with the inclusion of rescue medications in the study design.68 
28 
29 The product’s competition: 
30 
31 Barrier: Competing services/competing trials 
32 
33 Potential participant’s being able to access information or support services similar to 
34 those being offered as part of a study in the recruitment centre or local area, was 
36 seen as a barrier to recruitment. Patients were able to access similar therapies and 
37 support services without having to accept the restriction of randomisation.
44, 71 
38 Competing trials recruiting from a similar patient population was also seen as barrier 




3 Price: Managing the price 
43 
Type of costs: 
45 
Barrier: Patient’s condition and illness 
47 
Patients and caregivers being too burdened by the illness to participate27, 46, 56, 58, 62 
49 and the reality of having to deal with the unpredictable nature of the patient’s disease 
50 in the recruitment process
56, 63 were seen as significant barriers. The right time to 
51 approach was seen as an issue in one study, 
33 with patients citing the time around 
52 their initial diagnosis being the wrong time whilst others offered the intervention at 
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2 
3 
4 Barrier: Carer and patient gatekeeping 
5 
6 Gatekeeping by caregivers was also identified as an issue 46, 58, 72 with reports  of 
7 carers feeling protective towards their loved ones 46, 58, 72   so blocking researcher 
8 access to the patient. These findings correspond with a recent review focusing on 
10 gatekeeping in palliative care research generally.13 In addition, this review identified 
11 ‘gatekeeping’ by patients also as an issue in studies that aimed to recruit 
12 patient/carer dyads. This took the form of patients refusing to allow their caregivers 
13 to be approached49 or expressing concerns about the additional burden the study 
15 would place on their caregivers as well as making a decision that the caregiver 
16 would not derive any benefit from being involved in the research.33 
17 
18 Minimising the costs 
19 
20 Facilitator: Minimise burden for participants 
21 
22 There was consensus among a group of palliative care trial experts that recruitment 
23 success depended on minimising the burden of taking part in a trial for patients, 
24 carers and clinical staff.68 This involved limiting what was required from those 
25 participants who agreed to take part in a study. 
26 
27 Strategies: Consent 
28 
29 Strategies to minimise the costs of taking part in the study for participants were 
30 related to the informed consent process. Recruitment over the phone using verbal 
31 consent procedures was seen as a successful recruitment strategy for enrolling 
32 caregivers as they were sometimes unavailable at the time of patient consent. 66 This 
33 allowed carers to be contacted and recruited at a later point in time and it prevented 
35 the delays which can be associated with face to face consent. The use of advance 
36 consent to improve recruitment rates has been used in two feasibility RCTs
34, 65 and 
37 was found to be a workable consent process for patients who are unable to give 
38 consent at the time of randomisation. The use of Zelen consent (only those 
39 randomised to the experimental treatment need to be individually consented) versus 
40 cluster consent was tested within a feasibility RCT.
42 The findings suggested cluster 
41 randomisation may be a more helpful approach for increasing recruitment rates in 
42 trials with dying patients as nurses were reluctant to approach dying patients for 
43 consent to change of treatment. 
44 
45 4 Place: Improving accessibility 
46 
47 Barrier: Recruitment setting 
48 
49 The issue of travel was identified as a reason for patients declining a quality of life 
50 RCT71 in an oncology hospital as these types of interventions can often be provided 
51 locally while cancer treatment trials are only available in oncology units. Late referral 
52 to hospice services was also seen as a barrier to recruitment as patients were often 
53 too ill to take part in the study.69, 72 Hospice catchment areas could also be too small 
54 to provide the necessary pool of potentially eligible patients.72 Attempting to recruit 
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1 Recruitment SR 
2 
3 
4 trust with participants during such a stressful time can be difficult.41, 67 The role of 
5 specialist palliative care as a hospital consulting rather than admitting service was a 
6 barrier in a trial recruiting patients with malignant bowel obstruction.57 In contrast, 
7 recruiting participants after discharge was seen as more difficult in a couple of 
8 papers46, 58 with the feeling participants can be less receptive.46 The physical 
9 environment and the often complex nature of patient consultations in the outpatient 
10 setting are seen to make approaching participants more difficult.46, 56 
12 
Strategy: Increase the number of recruitment centres 
14 
Increasing the number of recruitment sites during the trial to increase the pool of 
16 potential participants was a strategy employed by a number studies to improve their 
17 recruitment rates.
26, 44, 71 Some studies were set up as multi centre studies but this 
18 did not always guarantee recruitment success.
37, 50 
19 
20 5 Promoting the study 
21 
22 Facilitators: Key/careful messaging/flexibility and persistence 
23 
24 The importance of paying attention to key and careful messaging when discussing a 
25 trial with patients, carers and clinical staff to provide reassurance and to address any 
27 concerns was seen as important.17, 26, 39, 45, 46, 55, 68 Recruiting staff also need to 
28 ensure they are flexible and demonstrate respectful persistence46, 66 while 
29 developing a rapport with the patient.66 
30 
31 Strategy: Role play/scripts 
32 
33 The use of role play and scripts to ensure those involved in the recruitment process 
34 use pre-defined key messaging when introducing a study to patients and carers is 
36 seen as a useful strategy.17, 26, 37, 41, 54, 68 One study described how it had refined its 
37 recruitment script during its pilot study to avoid introducing terms such as hospice 
38 and end-of-life care early on and decided to focus on quality of life instead.41 
39 
40 6 Working with partners 
41 
42 This aspect of the ‘Social Marketing Mix Framework’ is divided into three areas: 
43 barriers to partnering, partner education and partner referrals and recruitment.  
45 
Barriers to partnering 
47 
48 Barrier: Health care professional gatekeeping 
49 
50 ‘Gatekeeping’ was seen as a barrier to recruitment to RCTs in palliative care with the 
51 majority of papers identifying health care professional gatekeeping as the most 
52 difficult issue to overcome.
32, 35, 44, 46, 49-52, 55, 56, 61, 64, 70, 71 Gatekeeping in this context 
53 is when health care professionals prevent the researcher from approaching eligible 
54 patients and/or carers to discuss taking part in a study. This was related to the 
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2 
3 
4 research,32, 50 seeing patients as being too poorly35, 38, 46, 64 or emotionally 
5 distressed38, 56 or too stressed to be approached.49 A lack of belief in the 
6 intervention, 44, 61, 71 concerns regarding randomisation,38, 44, 71 the use of placebo32, 
8 
47, 69 and clinical equipoise, 44, 52, 71 lack of confidence discussing a challenging 
9 study42, 51 and fear of discussing prognosis52, 53, 70 were also cited as possible 
10 reasons. 
11 
12 Barrier: Research ethics committee gatekeeping 
13 
14 
Research ethics committees (RECs) play an important role in ensuring ethical 
15 
standards are met in research and the rights of those taking part are protected. 
17 RECs were seen at times not to have a good understanding of palliative care 
18 research which led to a misapplication of their gatekeeping role.73 This resulted in 
19 overly paternalistic recruitment procedures being put in place such as face to face 
20 consent in the community by a Doctor32 and insisting patients were informed they 
22 had a prognosis of six months or less before they could be approached.69 
23 
24 Barrier: Resources 
25 
26 Recruitment to palliative care RCTs is seen as a costly and labour intensive process. 
27 A large number of patients have to be screened from a variety of settings in order to 
28 find the participants that are eventually recruited to the study and the majority of 
29 research staff time is spent screening and consenting rather than carrying out the 
31 intervention and collecting data.34, 38, 46, 58, 72 Not having the necessary staff available 
32 due to staff turnover or holidays,37 clinical staff being too busy41or lack of out of 






Strategy: Personal repeated contact with referral sources 
38 
39 
Personal and repeated contact with referral sources was seen as crucial to create 
40 
41 and maintain enthusiasm and motivation throughout the life of the study as well as 
42 address any concerns that may develop.
17, 37, 38, 53, 64 The approaches used included 
43 presentations, regular meetings and involvement of clinical staff in the study design 
44 and procedure development.
17 Identifying an enthusiastic study champion to assist 
45 
46 access to potential participants and help promote the study among patients and 
47 clinical staff was also seen as a valuable strategy.
46, 55, 60, 71 
48 
49 Partner referrals and recruitment 
50 
51 Facilitators: Support of lead clinicians/the usefulness of a trials cooperative 
52 
53 Support of lead clinicians is seen as a facilitator as this enhanced patient acceptance 
54 of the trial along33, 46 28, 39, 41, 44, 48 with promoting a research culture in the 
55 recruitment sites.44 The usefulness of a national palliative care clinical trial’s 
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2 
3 
4 recognised in one study. This resource was seen to help improve recruitment as it 
5 facilitated team based support, the sharing and dissemination of best practices and 
6 the opportunity to learn from each other.46 
7 
8 Strategy: Screening strategies 
9 
10 From the literature it would appear identifying and finding potential participants is one 
11 of the most significant recruitment challenges in palliative care RCTs with the 
12 
13 approaches used dependent on local resources and systems. A number of screening 
14 strategies are suggested which include ‘active questioning’ to identify patients with a 
15 particular symptom
26 or those who are on specific medication rather than relying 
16 purely on clinical notes
46 and reviewing clinical lists or notes which may include 
17 electronic database searches if the facilities are available.
46, 55, 72 Other strategies 
19 included incorporating the screening process into the regular palliative care service 
20 triage process,17, 37 using a screening algorithm26 and simplifying and minimising the 
21 screening process for clinicians.17 
22 
23 
Strategy: Financial incentives/recruitment progress reports 
24 
25 
Financial incentives for study site staff were used in one study to attempt to improve 
26 
sluggish recruitment with mixed results across sites.55 Monthly recruitment progress 
28 reports sent to individual sites were used in one study and it was felt this encouraged 
29 ‘healthy competition and camaraderie’.55 
30 
31 Strategy: Research staff on site 
32 
33 Having research staff on site to provide logistical and practical support to enhance 
34 study recruitment is the strategy discussed most frequently in the literature.17, 26, 28, 29, 
35 36, 37, 40, 46, 53-55, 60, 71 Some authors have seen this intervention as the one that had the 
37 greatest impact on their recruitment rates.26, 40 It can be seen to relieve the excessive 
38 burden of recruitment on busy clinical staff,17, 26, 36, 40, 53 help address the issue of 
39 gatekeeping,28, 29, 37 support relationship building,26, 40, 54 help keep a trial visible,71 
40 allow direct access to participants46 and provide consistency.17 
42 
43 But it is important to note that in some trials this does not always appear to be the 
44 case and the issue of gatekeeping remained a problem despite the presence of a 
45 research nurse.
35 The issue of research staff not being available at the ‘right time’ to 
46 approach potential participants was sometimes seen as a problem with patients 
47 






53 Main findings/results of the study: 
54 
55 This review has shown that the barriers to recruitment and the potential strategies 
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2 
3 
4 anecdotal evidence. There are likely to be issues to consider for most studies, such 
5 as the need to pay attention to key and careful messaging, plan for adequate 
6 resources to find your participants, ensuring you have the support of the lead 
8 clinician and gatekeeping by health care professionals, but the lack of evidence 
9 highlights the need for more methodological studies to be embedded within trials 
10 including nested trials of recruitment strategies. 
11 
12 Using a marketing approach in palliative care could appear to be controversial but it 
13 could be argued that it actually puts the patient or carer at the centre of the process 
15 as it requires the researcher to focus on ‘the needs, wants, and preferences of the 
16 target audience’ (p10).14 Recruitment is a complex process and needs careful 
17 planning before the study is started. The ‘Social Marketing Mix Framework’ may help 
18 researchers better understand the processes underpinning recruitment and influence 
20 the design of their recruitment plan and how they implement this plan in practice.14 
21 The framework can help those involved in trials apply general recruitment principles 
22 while acknowledging the need to take trial specific and local circumstances into 
23 account. For example, one of the challenges identified in the literature was the issue 
25 of high refusal rates and this was not always related to the patient’s condition. Their 
26 refusal sometimes appeared to be related to their concerns about the ‘product’ which 
27 in social marketing terms relates to the intervention that is being offered in the study. 
28 A lack of belief in the intervention or the control, the feeling the intervention was not 
30 needed or having a particular preference for a certain treatment arm were discussed 
31 as reasons for refusal. Under the ‘Social Marketing Framework’ ensuring the 
32 ‘product’ meets the needs of the target audience is a key consideration when 
33 designing a study which in practice is reflected in the increasing requirement for 
34 patient and public involvement to be involved in the study design process. 
74 
36 
37 The role of health care professionals in recruitment to palliative care RCTs is 
38 fundamental and a plan of a how a study will work with its partners to meet its 
39 recruitment goals is crucial. ‘Working with partners’ with its focus on ‘partner 
40 education’, ‘partner referrals and recruitment’ and ‘barriers to partnering’ is a key 
42 aspect of the marketing framework applied in this review and is linked to the 
43 concepts of ‘Place’ and ‘Promotion’. For example, this refers to the location where 
44 recruitment activity takes place as well as the way in which the health care 
45 professional presents the study to the patient. 
47 
However, ‘Product’ and ‘Price’ are applied to the patient and/or carer and not the 
49 partner under this framework which may not fully capture the complexities of 
50 recruitment in palliative care. For example, clinicians struggling to accept the 
51 intervention or randomisation and feeling the emotional costs of approaching a 
52 patient or carer at a difficult time in their lives, making it hard for them to balance the 
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3 
4 Strengths and weaknesses/limitations of the study: 
5 
6 To the authors knowledge this is the first review to synthesise the evidence related to 
7 the barriers and facilitators to recruitment to RCTs in palliative care. The search 
8 strategy and approach used was thorough in this review, however, the authors do 
9 not claim to have identified and reviewed all published palliative care RCTs papers 
10 for reported barriers and facilitators to recruitment. The review findings are largely 
11 based on researcher anecdotal evidence so should be interpreted with caution. This 
12 is however, the level of evidence that is currently underpinning our understanding of 
13 recruitment issues in palliative care RCTs. 
15 
What this study adds: 
16 
17 This review is unique in this field as it uses a theoretical framework, the ‘Social 
18 Marketing Mix Framework’, to explore the barriers and facilitators to recruitment to 
19 RCTs in palliative care. Using theory in the review process can help the reviewer and 
20 reader assess how applicable and generalisable the findings of a review can be in 
21 practice. This review builds upon the findings of a recent qualitative review into 
23 gatekeeping in palliative care research and provides an insight into the some of the 
24 factors that may be at play during the trial recruitment process.
13 This review can 
25 help those involved in recruitment identify the factors they should consider when 
26 planning and implementing a recruitment strategy for any palliative care research 
27 study and not just a RCT. Reviews that focus purely on ‘tested’ recruitment 
28 strategies or interventions are important but their findings can be complemented by 
29 work that adopts a more qualitative approach as they have the potential to ‘elicit and 
30 identify the hidden challenges’ that make up this important clinical activity.
75 
31 
32 Implications for research and clinical practice 
33 
34 There is a need for more methodological research focusing on recruitment to 
35 palliative care RCTs. There are clearly themes mentioned more frequently in the 
36 literature that would suggest they are significant in clinical research but without the 
37 research to explore or address these issues further it is likely palliative care RCTs 
38 will continue to struggle to reach their recruitment targets. The benefits of using 
39 qualitative research to address recruitment related issues such as patient and 
40 recruiter concerns regarding randomisation in the early stages of trial development 
41 have been seen in the field of cancer treatment trials. 76 This approach appears to be 
42 increasingly incorporated into the design of palliative care feasibility RCTs. 62, 77 
44 Feasibility studies have the potential ‘to design out’ any issues that may negatively 
45 impact on a trials recruitment success or demonstrate that a study is in fact not 
46 feasible before progressing to a more costly full scale RCT. The use of embedded 
47 clinical trials to test recruitment strategies is another approach that is being 
48 developed in the field of trial methodology 
78 and has the potential to be used within 
49 palliative care research along with the growing recognition of the importance of 





54 The ‘Social Marketing Mix Framework’ can help guide researchers when planning 
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2 
3 
4 needed to help address the issue of poor recruitment to palliative care RCTs. The 
5 findings of this review are applicable to all palliative care research and not just 
6 randomised controlled trials. 
8 
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 Search strategies 
Medline via 
EBSCOhost 
- palliat* or 
- hospice* or 
- terminal care or 
- terminal care/ (not exploded) or 
- palliative care/ or 
- palliative medicine/ and 
- randomi*ed controlled trial* or 
- randomised controlled trial/ 
(publication and topic) 
- limits: human, 01/01/1990 to 




- palliat* or 
- hospice* or 
- terminal care or 
- palliative care/ or 
- terminally ill patients/ or 
- terminal cancer/ and 
- clinical trials/ or 
- randomi*ed controlled trial* 
- limits 01/01/1990 to 08/10/2016, 




- hospice* or 
- terminal care or 
- palliative care/ or 
- terminal care/ (not exploded), and 
- Randomi*ed Controlled Trial*, or 
- Clinical Trials/ (exploded), or 
- randomised controlled trial/ 
- limits 01/01/1990 to 08/10/2016, 
human and exclude Medline 
Embase via Ovid - palliat* or 
- hospice* or 
- terminal care or 
- exp palliative therapy/ or 
- terminal care/ and 
- randomi*ed controlled* or 
- randomized controlled trial/ 






























3 Supplementary Data 2: A hierarchy of evidence tool (adapted for the purposes 
4 of this review).24 
5 
6 7 Very well supported evidence: barriers/facilitators/strategies evaluated with a 
7 systematic review, meta-analysis (this section has been added for the purposes of 
8 this review). 
9 
10 6 Well supported evidence: barriers/facilitators/strategies evaluated with a 
11 prospective randomised controlled trial. 
13 
5 Supported evidence: barriers/facilitators/strategies evaluated with a control group 
15 and reported in a peer-reviewed publication. 
16 
17 4 Promising evidence: barriers/facilitators/strategies evaluated with a comparison 
18 group. 
19 
20 3 Acceptable evidence: barriers/facilitators/strategies evaluated with an 
21 independent assessment of outcomes, but no comparison group (e.g. pre and post 
22 testing, post testing only or qualitative methods) or historical comparison group (e.g. 
24 normative data). 
25 
26 2 Emerging evidence: (this section has been divided into two for the purposes of 
27 this review) 
28 
29  2 a Barriers/facilitators/strategies evaluated without an independent 
30 assessment of outcomes (e.g. formative evaluation, service evaluation 
32 conducted by host organisation). 
33  2 b Suggested as a possible barrier/facilitator/strategy by a group of expert 
34 health care professionals e.g. through a consensus exercise (stronger 
35 evidence than single author/research team opinion). 
37 
1 Expert opinion: (this section has been divided into three for the purposes of this 
39 review) 
40 
41  1a Expert opinion unsupported by evidence (Professional opinion):suggested 
42 as a possible barrier/facilitator/strategy by health care professionals 
43  1b Expert opinion unsupported by evidence (Researcher opinion): suggested 
44 
45 as a possible barrier/facilitator/strategy by researchers 
46  1c Expert opinion unsupported by evidence (Participants opinion): suggested 






















3 Supplementary Data Table 3: A table of the barriers and facilitators to 
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6 Working with 
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